1,560 results match your criteria Angioimmunoblastic Lymphoma
Am J Respir Crit Care Med 2018 Dec 10. Epub 2018 Dec 10.
Hamamatsu University School of Medicine, 2nd Division, Department of Internal Medicine, Hamamatau, Japan.
Retin Cases Brief Rep 2018 Nov 26. Epub 2018 Nov 26.
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Purpose: To report the multimodal imaging findings of immune recovery uveitis mimicking recurrent T-cell lymphoma after autologous bone marrow transplant therapy.
Methods: A 71-year-old man presented with posterior uveitis 6 weeks after chemotherapy and autologous bone marrow transplant for angioimmunoblastic T-cell lymphoma. Multimodal imaging included fluorescein angiography, fundus autofluorescence, and optical coherence tomography. Read More
Br J Haematol 2018 Nov 28. Epub 2018 Nov 28.
Division of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama-shi, Osaka, Japan.
Clin Lymphoma Myeloma Leuk 2018 Oct 13. Epub 2018 Oct 13.
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address:
Background: Peripheral T-cell lymphomas (PTCLs) are generally aggressive non-Hodgkin lymphomas that portend poor prognosis with currently available therapies. Bexarotene, a retinoic acid derivative, has efficacy in cutaneous T-cell lymphomas, but its activity in PTCL is unknown.
Patients And Methods: We conducted a retrospective, single-institution, review of off-label bexarotene therapy in patients with PTCL between 2005 and 2016. Read More
Int J Hematol 2018 Nov 14. Epub 2018 Nov 14.
Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0. Read More
Cutis 2018 Sep;102(3):179-182
Department of Dermatology, Saint Joseph Mercy Hospital, Ann Arbor, Michigan, USA.
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma that is characterized by lymphadenopathy, night sweats, fever, weight loss, and autoimmune phenomena. Cutaneous manifestations are present in up to 50% of cases, but few cases are reported in the dermatologic literature. We present a case of AITL that manifested in the skin. Read More
J Cutan Pathol 2018 Oct 28. Epub 2018 Oct 28.
Département de Biopathologie, CHU Montpellier, Hôpital Gui De Chauliac, Montpellier, France.
Background: We report the cases of three patients presenting skin lesions whose biopsies showed nodular polymorphic infiltrates consisting of lymphocytes, plasma cells, histiocytes, eosinophils, B blasts, and Hodgkin Reed-Sternberg (HRS)-like cells. Two of them were initially diagnosed as classical Hodgkin lymphoma (cHL), on the other hand, the last one as a B-cell lymphoma. All patients have been treated for angioimmunoblastic T-cell lymphoma (AITL). Read More
Cancer 2018 Oct 17. Epub 2018 Oct 17.
Early Phase Trials Unit, Churchill Hospital, University of Oxford, Oxford, United Kingdom.
Background: In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.
Methods: The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21-day cycle (3+3 design).
Results: A total of 39 patients were enrolled, 36 of whom received CXD101. Read More
Cytokine 2019 Jan 14;113:371-379. Epub 2018 Oct 14.
Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:
To better predict the outcomes of patients with peripheral T-cell lymphoma (PTCL), we measured the levels of various cytokines in serum samples from patients with PTCL and analyzed their clinical outcomes. We measured 34 cytokines in samples from 121 PTCL patients (55 PTCL-not otherwise specified (NOS), 44 angioimmunoblastic T-cell lymphoma (AITL), and 22 ALK anaplastic large cell lymphoma) at diagnosis. Their impact on clinical outcomes, including overall survival and complete response rate, were analyzed with other clinical variables. Read More
Ann Diagn Pathol 2018 Oct 9;37:107-117. Epub 2018 Oct 9.
Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China. Electronic address:
Background: Intestinal T-cell and NK/T- cell lymphomas are rare and aggressive. The diagnosis is quite difficult, especial in biopsy specimens. This study investigates the clinicopathological features of intestinal T-cell and NK/T-cell lymphomas to aid their differential diagnosis. Read More
Blood 2018 Nov 2;132(21):2305-2309. Epub 2018 Oct 2.
Service d'Hématologie Adultes, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
J Am Acad Dermatol 2018 Sep 18. Epub 2018 Sep 18.
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address:
Background: Epstein-Barr virus (EBV) positivity frequently presents in patients with nodal angioimmunoblastic T-cell lymphoma (AITL). However, the presence of EBV in skin lesions and its clinicopathological significance have not been evaluated.
Objective: To analyze the clinical and histopathological features of cutaneous AITL and evaluate EBV-positivity in skin tissue and its effects on clinicopathological features of AITL. Read More
Exp Ther Med 2018 Sep 6;16(3):2060-2065. Epub 2018 Jul 6.
Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, P.R. China.
Angioimmunoblastic T cell lymphoma (AITL)-associated hemophagocytic lymphohistiocytosis (HLH) rarely occurs with annular erythema multiforme-like rashes. The present case report describes a patient who was misdiagnosed with erythema multiforme at an early stage of the disease due to annular erythema multiforme-like eruptions. However, antihistamine treatment was ineffective. Read More
Oncology (Williston Park) 2018 08 15;32(8):e83-e89. Epub 2018 Aug 15.
The World Health Organization classification for peripheral T-cell lymphomas (PTCLs) continues to evolve based on genetic and clinical distinctions of each entity. In Part 1, an overview was provided of PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), and breast implant-associated ALCL. In Part 2, this review is extended to extranodal natural killer (NK)/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. Read More
Sci Rep 2018 Aug 27;8(1):12907. Epub 2018 Aug 27.
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
The aim of the present study was to analyze features and explore parameters that can help to predict prognosis for angioimmunoblastic T-cell lymphoma (AITL). A total of 117 patients with AITL were retrospectively analyzed. Multivariate analysis showed that β2 microglobulin (β2-M) ≥4. Read More
Pathology 2018 10 22;50(6):665-668. Epub 2018 Aug 22.
Department of Medical Oncology and Hematology, Medanta - The Medicity Hospital, Gurgaon, India.
Fam Cancer 2018 Aug 10. Epub 2018 Aug 10.
Department of Medical and Clinical Genetics, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver mutations have been found in TET2, IDH2, DNMT3A, RHOA, FYN, PLCG1, and CD28, whereas germline susceptibility to AITL has to our knowledge not been studied. The homogenous Finnish population is well suited for studies on genetic predisposition. Read More
Med Microbiol Immunol 2018 Aug 6. Epub 2018 Aug 6.
Department of Hematology, Shiga University of Medical Science, Otsu, Shiga, Japan.
We report a case of non-AIDS (acquired immunodeficiency syndrome), non-CAPD (Continuous Ambulatory Peritoneal Dialysis), non-cirrhotic, Mycobacterium avium peritonitis, which is a rare form of mycobacterial infection. A 66-year-old Japanese man who had been treated previously for angioimmunoblastic T-cell lymphoma (AITL), had developed disseminated M. avium infection. Read More
Indian J Med Res 2018 05;147(5):464-470
Department of Clinical Hematology, Christian Medical College & Hospital, Vellore, India.
Background & Objectives: Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin's lymphomas (NHLs), with universally poor outcome. This study was undertaken to provide data on demographics and outcomes of patients with PTCL who underwent treatment in a single tertiary care centre in southern India.
Methods: Retrospective study was done on all patients (age ≥18 yr) diagnosed with PTCL from January 2007 to December 2012. Read More
Oncology (Williston Park) 2018 07 15;32(7):e74-e82. Epub 2018 Jul 15.
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of diseases, with low incidence and unique epidemiology and pathobiology; they are usually clinically aggressive, with poor outcomes. There have been significant advances in our understanding of the molecular and signaling alterations seen in these malignancies. These observations have led to novel therapeutic strategies that have had a meaningful impact on outcomes. Read More
Turk J Haematol 2018 Aug 1. Epub 2018 Aug 1.
Hacettepe Üniversitesi Tıp Fakültesi Hematoloji Ünitesi, Ankara, Turkey.
Georgian Med News 2018 Jun(279):122-131
National Pirogov Memorial Medical University, Propedeutic Department of Internal Medicine; Department of Infection Diseases, Vinnytsya; Podilskiy Regional Oncological Center, Cytological Laboratory, Ukraine.
The problem of timely diagnosis and effective treatment of EBD-associated lymphoproliferative diseases is associated with a large variety of morphological and immunological manifestations, which require a powerful, highly specific immunohistochemical and molecular genetic research methods for the correct assessment. The article elucidates current information about the pathogenesis of oncogenic EBV infection, the main clinical forms of associated lymphoproliferative processes, their main diagnostic criteria. The given clinical case of angioimmunoblastic T cell lymphoma clearly demonstrates the complexity of the diagnostic process, underestimation of informativity and the importance of molecular genetic research, which led to the rejection of chemotherapeutic treatment, the rapid progression of the terminal stage of lymphoproliferative disease with the development of polyorganic failure and lifetime destruction, necrosis of the structural components of the tumor, as a result of which during the autopsy of morphological signs of lymphoma was not detected. Read More
Curr Opin Oncol 2018 Sep;30(5):277-284
Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Purpose Of Review: Peripheral T-cell lymphomas (PTCLs) represent diverse and aggressive malignancies, with few recent therapeutic improvements. Recent high-throughput genomic studies have revealed the complex mutational landscape of these rare diseases. These novel findings provide the grounds to a more comprehensive classification of these diseases, reflected in the 2017 WHO classification. Read More
Rheumatol Int 2018 Sep 18;38(9):1743-1749. Epub 2018 Jul 18.
Department of Internal Medicine F, The Chaim Sheba Medical Center, Tel Hahsomer, Israel.
It is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Read More
Int J Med Sci 2018 4;15(9):867-874. Epub 2018 Jun 4.
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute.
For peripheral T-cell lymphomas (PTCLs) patients, high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) has been an alternative treatment option, due to the lack of efficacy from conventional chemotherapy. While not all PTCLs could have benefit in survival from HDT/ASCT. The aim of this study was to evaluate the value of high-dose therapy combined with autologous peripheral blood stem cell transplantation (HDT/ASCT) in Chinese patients with Peripheral T-cell Lymphomas (PTCLs), in order to determine the cohort most suitable to receive HDT/ASCT. Read More
Med Clin (Barc) 2018 Jul 9. Epub 2018 Jul 9.
Servicio de Hematología Clínica, ICO-Girona, Hospital Universitario Dr. Josep Trueta, Girona, España.
Pathol Int 2018 Jul 10. Epub 2018 Jul 10.
Department of Hematology, Iizuka Hospital, Iizuka, Japan.
Although gamma heavy chain disease (γ-HCD) lesions occasionally morphologically resemble angioimmunoblastic T-cell lymphoma (AITL), no association has been described in detail due to the rarity of the disease. In this report, we present a rare manifestation of methotrexate (MTX)-associated lymphoproliferative disorders (LPDs) with AITL-like features accompanied by γ-HCD in a 75-year-old man with rheumatoid arthritis (RA). A biopsy specimen was evaluated using immunohistochemistry, clonal analyses of immunoglobulin V and T-cell receptor γ gene rearrangements by polymerase chain reaction, and Sanger sequencing for confirmation of the structure of deleted γ-HCD clones. Read More
J Mol Diagn 2018 Sep 5;20(5):677-685. Epub 2018 Jul 5.
INSERM U955 Équipe 9, Institut Mondor de Recherche Biomédicale, Créteil, France; Université Paris Est, Créteil, France; Département de Pathologie, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France.
Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma associated with chemoresistance and a poor prognosis. Various nonsynonymous mutations in the R172 residue of IDH2 are present in 20% to 30% of AITL patients. In addition to their diagnostic value, these mutations are potentially targetable, especially by isocitrate dehydrogenase (IDH) 2 inhibitor, and therefore their identification in a routine setting is clinically relevant. Read More
Am J Surg Pathol 2018 Oct;42(10):1402-1408
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Human herpes virus 6 (HHV-6) is a member of the β-herpesvirinae subfamily. Most people acquire HHV-6 primary infection early in life and reactivation may occur, most often in immunocompromised individuals, leading to various clinical manifestations. HHV-6 infected cells may be identified in lymph nodes in both reactive and neoplastic conditions. Read More
Rinsho Ketsueki 2018 ;59(6):688-694
Department of Hematology, Suita Municipal Hospital.
A 76-year-old woman was referred to our hospital because of fever, hemorrhagic skin lesion with pruritus, and severe thrombocytopenia. Anemia; marked eosinophilia; and elevated ALP, CRP, and soluble IL-2 receptor levels were observed on admission. Both anti-nuclear antibody and Coombs tests were positive. Read More
Joint Bone Spine 2018 Jun 30. Epub 2018 Jun 30.
Department of Internal Medicine, 40100 Dax, France.
Acta Derm Venereol 2018 Nov;98(10):981-982
Department of Pathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China.
Curr Hematol Malig Rep 2018 Aug;13(4):318-328
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-6842, USA.
Purpose Of Review: Peripheral T cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative neoplasms, with at least 29 distinct entities described in current WHO classification. Using present diagnostic approaches, more than a third of PTCL cases cannot be classified, hence designated as PTCL-not otherwise specified (PTCL-NOS). Herein, we summarize the current genomic findings and their role in the molecular pathogenesis in different PTCL entities. Read More
Leuk Lymphoma 2018 Jun 18:1-6. Epub 2018 Jun 18.
a Department of Medical Oncology, Sun Yat-sen University Cancer Center , State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine , Guangzhou , China.
Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma with unique clinical and pathological features. This study aim to design a prognostic model specifically for AITL, providing risk stratification in affected patients. A total of 115 newly diagnosed AITL patients were retrospectively analyzed. Read More
Hum Pathol 2018 Oct 6;80:145-151. Epub 2018 Jun 6.
Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833031, Taiwan; Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, Kaohsiung 83102, Taiwan. Electronic address:
Peripheral mature T and NK cell lymphomas consist of a heterogeneous group of neoplasms with cytogenetic and molecular diversities. TP53 mutation is involved in the events of tumorigenesis and present in a variety of cancer subtypes. However, TP53 mutation in peripheral mature T and NK cell lymphomas has not been extensively investigated. Read More
Rinsho Ketsueki 2018;59(5):574-587
Department of Pathology, School of Medicine, Kurume University.
Angioimmunoblastic T-cell lymphoma (AITL) originates from follicular helper T cells and shows variable biological and clinical presentations. The survival rate of patients with AITL did not correlate with T-cell clonality, the presence of EBV-infected cells, EBV-DNA copy number, or IgH rearrangements. However, tumor-associated macrophage/M2 macrophages significantly correlated with worse overall survival (OS). Read More
Nat Commun 2018 05 22;9(1):2024. Epub 2018 May 22.
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are few preclinical models of TCLs, which has hampered the development of effective therapeutics. Here we establish and characterize preclinical models of TCL. Read More
Zhonghua Xue Ye Xue Za Zhi 2018 Apr;39(4):265-270
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
To evaluate the prognostic value of lymphocyte-to-monocyte ratio (LMR) in angioimmunoblastic T cell lymphoma (AITL). Data of 64 patients diagnosed as AITL at the First Affiliated Hospital of Nanjing Medical University between June 2009 and July 2017, were analyzed retrospectively. Receiver Operator Characteristic (ROC) curve was used to calculate the cutoff value of LMR to divide this cohort of patients into high and low LMR groups. Read More
Blood 2018 Aug 16;132(9):935-947. Epub 2018 May 16.
Department of Medical Oncology and.
Patients with angioimmunoblastic T-cell lymphoma (AITL) and other peripheral T-cell lymphomas that harbor features of follicular helper T (T) cells have a very poor prognosis. These lymphomas commonly present with paraneoplastic autoimmunity and lymphopenia. RhoA G17V mutation is present in 60% of T-like lymphomas, but its role in tumorigenesis is poorly understood. Read More
Int J Lab Hematol 2018 May;40 Suppl 1:97-103
Haematopathology Unit, Hospital Clinic, Barcelona University, Barcelona, Spain.
Over the last decade, there has been a significant body of information regarding the biology of the lymphoid neoplasms. This clearly supports the need for updating the 2008 WHO (World Health Organization) classification of haematopoietic and lymphoid tumours. The 2017 WHO classification is not a new edition but an update and revision of the 4th edition. Read More
Lancet Haematol 2018 May;5(5):e190-e200
The Royal Marsden NHS Foundation Trust, London and Surrey, UK. Electronic address:
Background: Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients.
Methods: We did a phase 2, parallel-group, multicentre, open-label randomised trial in 47 hospitals: 46 in the UK and one in Australia. Read More
Blood 2018 Jul 26;132(3):245-253. Epub 2018 Apr 26.
Department of Medicine A, University Hospital Münster, Münster, Germany.
Mature T- and natural killer (NK)-cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common T-cell lymphomas (peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphomas; anaplastic lymphoma tyrosine kinase-negative) as well as for many other entities. High-dose therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is widely recommended for consolidation after a complete or partial remission is achieved. Read More
J Med Case Rep 2018 Apr 20;12(1):101. Epub 2018 Apr 20.
Department of Internal Medicine, Wayne State University School of Medicine, Rochester Hills, MI, USA.
Background: Angioimmunoblastic T cell lymphoma is a rare malignancy, accounting for only 2% of all non-Hodgkin lymphomas, first described in the 1970s and subsequently accepted as a distinct entity in the current World Health Organization classification. Due to the paucity of this disease, there is still no identifiable etiology, no consistent risk factors, and the pathogenesis remains unclear.
Case Presentation: An 83-year-old Caucasian man presented to an emergency department with palpitations and was found to have atrial fibrillation. Read More
Blood 2018 May 17;131(21):2320-2330. Epub 2018 Apr 17.
Department of Pathology and Laboratory Medicine and.
T-cell lymphomas are a heterogeneous group of rare malignancies with overlapping clinical, immunologic, and histologic features. Recent advances in our understanding of T-cell differentiation based on gene expression profiling, next-generation sequencing, and transgenic mouse modeling studies have better elucidated the pathogenetic mechanisms underlying the diverse biology of T-cell lymphomas. These studies show that although genetic alterations in epigenetic modifiers are implicated in all subtypes of T-cell lymphomas, specific subtypes demonstrate enrichment for particular recurrent alterations targeting specific genes. Read More
Oncotarget 2018 Mar 1;9(22):16124-16133. Epub 2018 Mar 1.
Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, Spain.
The overlap of morphology and immunophenotype between angioimmunoblastic T-cell lymphoma (AITL) and other nodal peripheral T-cell lymphomas (n-PTCLs) is a matter of current interest whose clinical relevance and pathogenic background have not been fully established. We studied a series of 98 n-PTCL samples (comprising 57 AITL and 41 PTCL-NOS) with five T antibodies (CD10, BCL-6, PD-1, CXCL13, ICOS), looked for mutations in five of the genes most frequently mutated in AITL (, and ) using the Next-Generation-Sequencing Ion Torrent platform, and measured the correlations of these characteristics with morphology and clinical features. The percentage of mutations in the and genes was similar (23. Read More
Clin Case Rep 2018 04 10;6(4):750-752. Epub 2018 Feb 10.
Michigan State University/Sparrow hospital B301, 788 Service Road East Lansing Michigan 48824.
Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of NHL and usually presents in the late stage due to the atypical laboratory findings. Immunohistochemistry of the lymph node in AITL is characterized by positive CD2, CD3, CD4, CD10, CXCL-13, PD1 often BCL-6 and CD20 positive. Meshworks of follicular dendritic cells are seen outside follicles with CD21 and CD23 stains. Read More
Aesthet Surg J 2018 Apr 9. Epub 2018 Apr 9.
Department of Plastic and Reconstructive Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Lymphomas associated with implants are predominantly of T-cell type-with anaplastic large cell lymphoma (ALCL) being most reported. That said, to date 6 cases of B-cell lymphoma associated with breast implants have been reported. All cases exhibited unilateral breast involvement. Read More
Appl Immunohistochem Mol Morphol 2018 Apr 7. Epub 2018 Apr 7.
Department of Pathology, Stanford University, Stanford, CA.
Here, we utilize a high throughput sequencing panel that covers several genes known to be recurrently mutated in certain T-cell lymphoma subtypes as well as genes frequently mutated in other hematolymphoid malignancies, including myeloid neoplasms. This panel was applied to formalin-fixed, paraffin-embedded tissue from 84 biopsies from 78 patients selected for this study. The biopsies included ones a with a diagnosis of T-cell lymphoma (n=79), including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n=26) and angioimmunoblastic T-cell lymphoma (AITL; n=13), as well as 5 cases of atypical T-cell proliferations. Read More
Cancer Res Treat 2018 Apr 2. Epub 2018 Apr 2.
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Purpose: Determine the frequency and prognostic value of circulating Epstein-Barr virus (EBV) DNA copy number in angioimmunoblastic T-cell lymphoma (AITL) patients who were treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) regimens.
Materials And Methods: Sixty newly-diagnosed AITL patients were retrospectively enrolled in the present study. All patients were treated with DA-EPOCH regimen. Read More
Front Oncol 2018 7;8:54. Epub 2018 Mar 7.
Institute of Pathology and Medical Genetics, University Hospital of Basel, Basel, Switzerland.
Purpose: Targeting cancer cells by modulating the immune system has become an important new therapeutic option in many different malignancies. Inhibition of CTLA4/B7 and PD1/PDL1 signaling is now also being investigated and already successfully applied to various hematologic malignancies.
Methods: A literature review of PubMed and results of our own studies were compiled in order to give a comprehensive overview on this topic. Read More